Status:
COMPLETED
An Open-Label Study of N-Acetyl Cysteine in Pathological Gambling
Lead Sponsor:
University of Minnesota
Conditions:
Pathological Gambling
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
After completing all screening evaluations, subjects will receive unblinded N-Acetyl Cysteine 600 mg/day for 2 weeks. The dose will be raised to 1200 mg/day at visit 4 and to 1800 mg/day at visit 6 un...
Detailed Description
Before beginning N-Acetyl Cysteine, all subjects will receive a psychiatric, medical, and family history evaluation as well as the Structured Clinical Interview for DSM-IV (SCID-P) for Axis I disorder...
Eligibility Criteria
Inclusion
- Men and women age 18-65
- Current DSM-IV PG
Exclusion
- Unstable medical illness on physical examination
- History of seizures
- Myocardial infarction within 6 months
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Clinically significant suicidality
- Lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder
- Current or recent (past 3 months) DSM-IV substance abuse or dependence
- Illegal substance within 2 weeks of study initiation
- Initiation of psychotherapy or behavior therapy from a mental health professional within 3 months prior to study baseline
- Previous treatment with N-Acetyl Cysteine
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT00273702
Start Date
January 1 2006
End Date
September 1 2006
Last Update
April 30 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Minnesota
Minneapolis, Minnesota, United States, 55454